Abbott’s dissolvable below-knee stent, originally designed for heart disease patients, is now being used in patients with severe vascular disease. The stent widens clogged blood vessels and then dissolves into the vessel’s walls over three years. It also delivers a drug to prevent scar tissue formation, a common issue with traditional metal stents. Abbott’s first dissolvable stent for coronary artery disease received FDA approval in 2016 but was later pulled from the market due to low commercial uptake and mixed results in clinical trials. The device is now being repurposed for patients with severe vascular disease, offering a potentially more effective and long-lasting treatment option for this patient population.
June 21, 2024
Artificial Intelligence
FDAcop
